Crossmark

Comment on: “The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab”

Published Online: 2024-12-20

Published Print: 2025-02

Authors

Giusti, Raffaele https://orcid.org/0000-0003-4592-8868
License Information

Text and Data Mining valid from 2024-12-20

Version of Record valid from 2024-12-20
More Information

Article History

Accepted: 8 December 2024

First Online: 20 December 2024

Declarations

:

: No funding to declare.

: None pertain to this letter.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current